Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from FATE

Fate/strange Fake anime finally gets a release date – almost 300 days after its world premiere

Fate/strange Fake hits screens in January

Total Film

Fate: Reawakened gives the nostalgic 20-year-old action RPG series a new lease on life

Time to take the dog for one last walk in this ageing predecessor to Torchlight.

PC Gamer

After 24 years, the legendary visual novel that put the Fate/stay night devs on the map has an English remake, and it's out-reviewing FF7 Rebirth, Hades 2, and more

Tsukihime: A Piece of Blue Glass Moon is here, and it's a critical darling

GamesRadar

From analysis to the latest developments in health,
read the most diverse news in one place.

Best anime: 25 shows to watch in 2025

Total Film

Jared Goff is the Lions nominee for the Walter Payton NFL Man of the Year award

The award honors off-field excellence and community service and is highly coveted by players

USA Today Sports Media Group

In fighting gun crime, Canada has an American problem

A Texas man bought dozens of guns from licensed dealers in the state before illegally reselling at least 16, U.S. officials say. Twelve were traced to crimes committed in America. The other four were traced to crimes in Canada.

Reuters

Recap: Fate Therapeutics Q1 Earnings

Fate Therapeutics (NASDAQ:FATE) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…

StockNews.com

What 4 Analyst Ratings Have To Say About Fate Therapeutics

Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings:

Benzinga

Looking Into Fate Therapeutics's Return On Capital Employed

Benzinga Pro data, Fate Therapeutics (NASDAQ:FATE) reported Q4 sales of $17.07 million. Earnings fell to a loss of $68.62 million, resulting in a 58.45% decrease from last quarter.

Benzinga

Fate Therapeutics: Q4 Earnings Insights

Fate Therapeutics (NASDAQ:FATE) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga

2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch

Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century Therapeutics Inc (NASDAQ:

Benzinga

People

Jared Goff

1,641 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Ginkgo Bioworks Holdings Inc

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.